Onco Wiki / Bandera roja

Active or latent infection requiring resolution / prophylaxis before initiating any anti-...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-MCL-INFECTION-SCREENING
TipoSeñal de alerta
Situaciónreviewed 2026-04-27 | pending_clinical_signoff
EnfermedadesDIS-MCL
FuentesSRC-ESMO-MCL-2024 SRC-NCCN-BCELL-2025

Origen de la bandera roja

DefiniciónActive or latent infection requiring resolution / prophylaxis before initiating any anti-CD20-containing MCL induction (R-CHOP, BR, R-DHAP, Nordic, R-bendamustine + cytarabine): HBsAg-positive, anti-HBc-positive (occult HBV), HCV-RNA-positive, HIV-positive, or active TB. Particular vigilance with bendamustine combinations (HBV reactivation rates highest among anti-CD20 partners).
Dirección clínicaAtención
Categoríadetección de infecciones

Lógica de activación

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hbc_total",
      "value": "positive"
    },
    {
      "finding": "hcv_rna",
      "value": "positive"
    },
    {
      "finding": "hiv_status",
      "value": "positive"
    },
    {
      "finding": "active_tb",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notas

HBsAg+ → entecavir/tenofovir prophylaxis from –7d through +12-18 mo post-last anti-CD20 (extended given autoSCT consolidation often follows). occult HBV (anti-HBc+ HBsAg-negative) on bendamustine: reactivation rates 10-20% — monitor HBV-DNA q1-3mo or pre-emptive prophylaxis. Bendamustine reactivates HSV / VZV — acyclovir prophylaxis routine. PJP prophylaxis (TMP-SMX) on prolonged R-CHOP / Nordic (T-cell lymphopenia post HD-AraC) and ongoing BTKi maintenance. HIV+ MCL: rare; full-dose chemoimmuno + ART optimization. autoSCT feasible in HIV+ if controlled.

Utilizado por

Indicación